Axsome Therapeutics Stock Price, News & Analysis (NASDAQ:AXSM) $68.59 +1.16 (+1.72%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$67.16▼$69.3150-Day Range$57.42▼$73.0652-Week Range$53.71▼$91.29Volume386,359 shsAverage Volume827,326 shsMarket Capitalization$3.25 billionP/E RatioN/ADividend YieldN/APrice Target$105.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside53.8% Upside$105.50 Price TargetShort InterestBearish16.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.50Based on 2 Articles This WeekInsider TradingSelling Shares$828,293 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.06) to ($3.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector296th out of 948 stocksPharmaceutical Preparations Industry115th out of 421 stocks 3.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $105.50, Axsome Therapeutics has a forecasted upside of 53.8% from its current price of $68.59.Amount of Analyst CoverageAxsome Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.15% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 11.5, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 3.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.5 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Axsome Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 12 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows5 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $828,293.00 in company stock.Percentage Held by Insiders24.50% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.60% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.06) to ($3.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -15.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -15.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 27.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesDecember 3, 2023 | barrons.comUPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!November 27, 2023 | seekingalpha.comAxsome Therapeutics: Positive Q3, We Like The Launch Success StoryDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 22, 2023 | finance.yahoo.comAxsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7November 21, 2023 | finance.yahoo.comAxsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNovember 8, 2023 | markets.businessinsider.comBuy Rating on Axsome Therapeutics: Financial Growth and Promising Pipeline despite Minor SetbacksNovember 7, 2023 | markets.businessinsider.comHold Rating on Axsome Therapeutics: Unchanged Strategies and Revenue Forecasts Amid Concerns on Future Sales and Profitability TrendsNovember 7, 2023 | finance.yahoo.comAxsome (AXSM) Q3 Loss Widens, Revenues Surpass EstimatesDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 7, 2023 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comQ3 2023 Axsome Therapeutics Inc Earnings CallNovember 7, 2023 | seekingalpha.comAxsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)November 7, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sangamo Biosciences (SGMO), Axsome Therapeutics (AXSM)November 6, 2023 | finance.yahoo.comAxsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) Reports 244% YoY Growth in 3Q 2023 Product RevenueNovember 2, 2023 | finance.yahoo.comAxsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023October 30, 2023 | finance.yahoo.comAnalysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forOctober 24, 2023 | finance.yahoo.comAxsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 ConferenceOctober 17, 2023 | markets.businessinsider.comBuy Rating Assigned to Axsome Therapeutics Amid Positive Prescription Trends for AuvelityOctober 16, 2023 | seekingalpha.comAxsome Update: Buy At Dips And Hold ForeverOctober 12, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Cytokinetics (CYTK), Axsome Therapeutics (AXSM)October 11, 2023 | finance.yahoo.comAxsome Therapeutics Appoints Dr. Sue Mahony to its Board of DirectorsOctober 10, 2023 | finance.yahoo.comAxsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6October 9, 2023 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)October 4, 2023 | msn.comMizuho says market fears for Harmony's Wakix drug are "overblown"October 3, 2023 | markets.businessinsider.comMaintaining Buy Rating for Axsome Therapeutics: Steady Auvelity Sales and Anticipated Q3 Performance InsightsOctober 2, 2023 | finance.yahoo.comAxsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness WeekSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/05/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees502Year FoundedN/APrice Target and Rating Average Stock Price Target$105.50 High Stock Price Target$180.00 Low Stock Price Target$81.00 Potential Upside/Downside+53.8%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,130,000.00 Net Margins-90.33% Pretax Margin-89.75% Return on Equity-88.79% Return on Assets-35.35% Debt Debt-to-Equity Ratio0.66 Current Ratio4.46 Quick Ratio4.38 Sales & Book Value Annual Sales$50.04 million Price / Sales64.86 Cash FlowN/A Price / Cash FlowN/A Book Value$2.52 per share Price / Book27.22Miscellaneous Outstanding Shares47,320,000Free Float35,727,000Market Cap$3.25 billion OptionableOptionable Beta1.94 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 55)Founder, Chairman, CEO & President Comp: $1.32MMr. Nick Pizzie CPA (Age 48)M.B.A., Chief Financial Officer Comp: $732.94kMr. Mark L. Jacobson (Age 40)COO & Secretary Comp: $784.66kMr. Hunter Murdock Esq. (Age 43)General Counsel & Secretary Comp: $735.39kDr. Amanda Jones Pharm.D. (Age 40)Senior Vice President of Clinical Development Ms. Lori Englebert M.B.A. (Age 45)Executive Vice President of Commercial & Business Development Joseph Debrah-Afful CPAM.B.A., Director of FinanceMore ExecutivesKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDCytokineticsNASDAQ:CYTKHUTCHMEDNASDAQ:HCMUltragenyx PharmaceuticalNASDAQ:RAREEvotecNASDAQ:EVOView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 37,843 shares on 12/1/2023Ownership: 0.502%Neo Ivy Capital ManagementBought 2,912 shares on 11/30/2023Ownership: 0.006%Deutsche Bank AGBought 2,407 shares on 11/24/2023Ownership: 0.127%Graham Capital Management L.P.Bought 13,255 shares on 11/22/2023Ownership: 0.028%Walleye Capital LLCBought 200 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price target for 2024? 9 Wall Street analysts have issued 12-month price objectives for Axsome Therapeutics' stock. Their AXSM share price targets range from $81.00 to $180.00. On average, they anticipate the company's stock price to reach $105.50 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2023? Axsome Therapeutics' stock was trading at $77.13 at the beginning of 2023. Since then, AXSM stock has decreased by 11.1% and is now trading at $68.59. View the best growth stocks for 2023 here. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our AXSM earnings forecast. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its earnings results on Monday, November, 6th. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.24) by $0.08. The company earned $57.79 million during the quarter, compared to the consensus estimate of $54.88 million. Axsome Therapeutics had a negative net margin of 90.33% and a negative trailing twelve-month return on equity of 88.79%. During the same period in the previous year, the business posted ($1.03) EPS. What ETFs hold Axsome Therapeutics' stock? ETFs with the largest weight of Axsome Therapeutics (NASDAQ:AXSM) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), iShares U.S. Pharmaceuticals ETF (IHE) and Principal Healthcare Innovators ETF (BTEC).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (9.49%), FMR LLC (3.93%), Alethea Capital Management LLC (1.60%), Northern Trust Corp (0.74%), Eventide Asset Management LLC (0.73%) and Adage Capital Partners GP L.L.C. (0.69%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AXSM) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.